Left Ventricular Hypertrophy and Spironolactone in End Stage Renal Disease
Information source: Allegheny General Hospital
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Kidney Failure, Chronic
Intervention: Spironolactone (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Allegheny General Hospital Official(s) and/or principal investigator(s):
Richard Marcus, Principal Investigator, Affiliation: Allegheny General Hospital
Summary
The hypothesis of this trial is to assess the effect of spironolactone on heart size and
mass
Clinical Details
Study design: Treatment, Non-Randomized, Open Label, Single Group Assignment
Primary outcome: Left ventricular mass
Detailed description:
Dialysis patients have significant morbidity and mortality associated with left ventricular
hypertrophy and cardiac failure. Aldosterone may have an important role in the development
of myocardial hypertrophy and remodeling. Animal studies have demonstrated beneficial effects
of aldosterone antagonists on myocardial hypertrophy, and human studies have shown
significant survival benefit in a non-dialysis population with congestive heart failure. This
study evaluates the effect of spironolactone (an aldosterone receptor antagonist) on cardiac
hypertrophy in the end-stage renal disease population.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- hemodialysis patients
Exclusion Criteria:
- non compliance
- hyperkalemia
- pregnancy
- expected survival less than 9 months
Locations and Contacts
Allegheny General Hospital, Pittsburgh, Pennsylvania 15212, United States
Additional Information
Last updated: October 23, 2007
|
